Liminal BioSciences Inc. PFSCF

Primary Symbol: LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc.

Bullboard Posts

Post by MYSTICALon May 10, 2013 9:49pm

130 Views

Post# 21365467

Strong outlook

Revenues of $4.4 million in Q1 2013, an increase of $3.3 million compared to Q1 2012
Revenues expected to exceed $11.0 million by the end of June 2013, compared to $7.4 million for the first half of 2012
2013 revenues expected to significantly exceed 2012 revenues
IND for PBI-4050 expected to be filed in Q3 2013
ProMetic BioProduction's plasma purification and manufacturing facility to be operational in Q4 2013
2013 corporate objectives communicated
New members elected to Board of Directors